<?xml version="1.0" encoding="UTF-8"?>
<fig id="cancers-13-00251-f003" orientation="portrait" position="float">
 <label>Figure 3</label>
 <caption>
  <p>High levels of p53β are associated with prolonged overall survival in patients with advanced stage (III/IV) breast cancer (TCGA breast cancer (BRCA) data [
   <xref rid="B24-cancers-13-00251" ref-type="bibr">24</xref>,
   <xref rid="B25-cancers-13-00251" ref-type="bibr">25</xref>]). 
   <italic>N</italic> = 277; unadjusted 
   <italic>p</italic>-value = 0.00132. The “expression low” cohort represents the following combination of samples: HER2 negative (39.6%, 
   <italic>N</italic> = 80), HER2 positive (17.3%, 
   <italic>N</italic> = 35), NA (36.6%; 
   <italic>N</italic> = 74; including HER2 equivocal), and triple-negative breast cancer (6.4%, 
   <italic>N</italic> = 13). The “expression high” cohort represents the following combination of samples: HER2 negative (41.3%, 
   <italic>N</italic> = 31), HER2 positive (16.0%, 
   <italic>N</italic> = 12), NA (32.0%; 
   <italic>N</italic> = 24; including HER2 unequivocal), and triple-negative breast cancer (10.7%, 
   <italic>N</italic> = 8). The cohort was 32.5% (
   <italic>N</italic> = 90) TP53 mutant and 67.5% (
   <italic>N</italic> = 187) TP53 wild type (WT). HER2-negative status was determined as; (1) ER−, PR+; (2) ER+, PR−; (3) ER+, PR+; or (4) ER+, PR indeterminate. Methods for data analysis can be found in 
   <xref ref-type="app" rid="app1-cancers-13-00251">supplementary material</xref>.
  </p>
 </caption>
 <graphic xlink:href="cancers-13-00251-g003" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
